Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07212868 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 2 changed
See other at-risk trials from The University of Texas Health Science Center at San Antonio

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Eligibility criteria expanded, about 21 words
    • Site contacts updated at 1 of 2 sites
  2. Site contacts updated at 1 of 2 sitesv6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 1, 2025 to Feb 25, 2026
    • Site details revised at 2 of 2 sites
    v5
  4. Site contacts updated at 1 of 2 sitesv4
  5. Start date: Oct 1, 2025 to Dec 1, 2025
    • Site contacts updated at 1 of 2 sites
    v3
  6. Secondary endpoints: details revised at 2 of 3 entriesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is involved with measuring glucose metabolism with glucagon infusion and glucagon receptor blockade. We use an investigational drug called REMD 477. "Investigational" means that the has not yet been approved by the U.S. Food \& Drug Administration (FDA). REMD-477 is a monoclonal antibody (an antibody made by cloning a unique white blood cell) that blocks the effect of glucagon.
Trial Details
NCT Number NCT07212868
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Non-Diabetic
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov